Navigation Links
ThromboGenics Establishes Level 1 ADR Program for US Investors
Date:9/29/2013

New York, NY 10005

In the U.S.: (866) JPM-ADRS  

Outside the U.S.: (+1 866  576-2377)

Or visit J.P. Morgan Depositary Receipts Services at http://www.adr.com.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.  

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

In Europe, JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA® in the UK, Germany, Denmark, Norway, Finland and Sweden.  

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction.  No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.


'/>"/>
SOURCE ThromboGenics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pittcon Establishes a Collaborative Program Resource Team for 2014
2. Alacrita Establishes U.S. Headquarters in Boston Area
3. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
4. FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation
5. RURO Adds Critical Level Monitoring Functionality to its Transgenic Animal Management Software ezColony
6. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
7. Desktop printing at the nano level
8. Low Blood DHA Levels Linked to Decreased Reading Ability and Memory Performance in Children
9. New Study Reveals that PEEK Polymer Spinal Cage Is Superior to Titanium in Surgical Treatment of Multilevel Cervical Spondylotic Myelopathy
10. Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference
11. IntraMed Diagnostics Announces Two Senior-Level Additions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Global Stem Cells Group ... stem cell treatment center in Quito, Ecuador, Feb. 24-March 6, 2016. The new facility ... the world. , Global Stem Cells Group CEO Benito Novas will host the ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Georgia World Congress Center in Atlanta, Georgia, will include 848 exhibitors (count as ... companies will be displaying products and services used by the scientific community in ...
(Date:2/12/2016)... SOUTH PLAINFIELD, N.J. , Feb. 12, 2016 ... today announced the second annual STRIVE (Strategies to ... for Duchenne muscular dystrophy (DMD). STRIVE provides funds ... collaborative programs that will make meaningful contributions to ... education or fostering development of future patient advocates. ...
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic ... Research and Discovery --> --> ... plan to sequence 100,000 individuals. It is intended to initially ... 7 of North and East Asian countries. ... project will focus on creating phased reference genomes for all ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
Breaking Biology News(10 mins):